New Gene Editing Candidate to Debut Data at Meeting
The therapy for hereditary angioedema nears a March 2027 FDA decision after new clinical data are presented this November.
Updated on Oct. 29, 2026 in Allergies

Live Poll
Would you prefer a single-dose genetic treatment over lifelong daily medication for a chronic condition?
Intellia Therapeutics will present new clinical data on its gene-editing candidate lonvo-z at the ACAAI 2026 Annual Scientific Meeting in Phoenix, Arizona, from November 12-16, 2026. This candidate is currently under review by the FDA for the treatment of hereditary angioedema, a condition that impacts roughly one in 50,000 individuals.
Why it matters
If approved, this in vivo CRISPR therapy could offer a new approach for managing hereditary angioedema. The FDA has set a target action date for the drug's application on March 10, 2027.
Data regarding lonvo-z will be shared through two oral and five poster presentations, representing a total of seven reports on the gene-editing candidate at the ACAAI meeting. Specific efficacy results are still under formal evaluation by the FDA.
The players
Intellia Therapeutics
A biotechnology company specializing in CRISPR-based gene editing therapies for genetic diseases.
FDA
The federal agency responsible for evaluating the safety and efficacy of new drugs and biologics.
The details
Lonvo-z is an in vivo CRISPR gene-editing therapy designed to inactivate the KLKB1 gene. By targeting this specific gene, the treatment aims to provide a long-term approach for managing hereditary angioedema symptoms. Further insights into the therapy, including findings related to 50 mg dosing, are expected to be disclosed during the upcoming sessions.
Timeline
November 12, 2026: Investor webcast and start of ACAAI meeting.
November 13, 2026: Five poster presentations occur.
November 14, 2026: Two oral presentations occur.
March 10, 2027: FDA PDUFA target action date for lonvo-z.
Health Landscape
The development of lonvo-z sits within the expanding field of in vivo CRISPR gene editing, which is currently moving from early-stage research into formal regulatory review. It marks a shift toward potentially curative, rather than symptom-focused, options for rare hereditary conditions.
Individuals managing hereditary angioedema should monitor news regarding the FDA's decision in March 2027 to understand how this therapy may eventually fit into existing treatment protocols. Discuss the potential impact of new gene-editing technologies on your long-term care plans with your specialist.
The takeaway
Lonvo-z represents an emerging CRISPR-based effort to address the underlying cause of hereditary angioedema. Patients should talk to their physician about current management standards and stay informed on upcoming FDA regulatory updates.
What happens next
The FDA is scheduled to reach a decision on the Biologics License Application for lonvo-z by March 10, 2027.
Further reading
For more on evolving research in this field, visit our guide on Allergies.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Would you prefer a single-dose genetic treatment over lifelong daily medication for a chronic condition?





